SCHEMBL22096038

SCHEMBL22096038

O=C(O)c1nonc1NCn1nnnc1Cc1cccc(Cl)c1

nearest known ligand 0.79

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 4/20 0.79
MAPT P10636 5/20 0.37
LMNA P02545 3/20 0.37
HCAR2 Q8TDS4 1/20 0.36
IDO1 P14902 3/20 0.36
PTK2 Q05397 1/20 0.35
HSD11B1 P28845 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TP53 P04637 1/20 0.34
GPR139 Q6DWJ6 1/20 0.34
MET P08581 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20048221 0.89 STAT5B (1.00) STAT5BHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL22096005 0.88 STAT5B (0.79) STAT5BMAPTLMNAHCAR2IDO1
SCHEMBL22096029 0.84 STAT5B (0.79) STAT5BLMNAKDM4EALDH1A1
SCHEMBL22096011 0.83 STAT5B (0.88) STAT5BALDH1A1
SCHEMBL22096004 0.82 STAT5B (0.82) STAT5BLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL22096021 0.82 STAT5B (0.82) STAT5BLMNAIDO1ALDH1A1SMN1; SMN2
SCHEMBL22096030 0.81 STAT5B (0.82) STAT5BHSD11B1ALDH1A1SMN1; SMN2MEN1
SCHEMBL22096012 0.80 STAT5B (0.83) STAT5BALDH1A1
SCHEMBL22096032 0.80 STAT5B (0.78) STAT5BIDO1KDM4EALDH1A1SMN1; SMN2
SCHEMBL22096031 0.80 STAT5B (0.78) STAT5BHSD11B1ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885MAPT 4829/4885LMNA 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.